Ferric carboxymaltose for sub-acute and chronic iron deficiency anemia in inherited platelet function defects
- PDF / 476,409 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 2 Downloads / 197 Views
CE-RESEARCH LETTER TO THE EDITOR
Ferric carboxymaltose for sub‑acute and chronic iron deficiency anemia in inherited platelet function defects Natalia Scaramellini1 · Marco Capecchi1,2 · Andrea Artoni2 · Silvia La Marca2 · Maria Domenica Cappellini1 · Irene Motta1,3 Received: 20 June 2020 / Accepted: 13 August 2020 © Società Italiana di Medicina Interna (SIMI) 2020
Abstract Inherited platelet function defects are characterized by sub-acute and chronic mucocutaneous bleedings leading to iron deficiency anemia (IDA). Oral supplementation is the mainstay of treatment of IDA; however, it can be insufficient to compensate the losses and is often associated with gastrointestinal (GI) side effects. Intravenous (IV) iron is indicated for severe anemia or to overcome GI intolerance. Previous IV iron formulations were limited by the risk of free iron toxicity and immunogenicity, while currently available compounds (ferumoxytol, iron isomaltoside and ferric carboxymaltose (FCM)) allow the administration of high doses with low immunogenicity. There are neither any randomized studies nor case reports evaluating the efficacy of FCM in patients with inherited platelet disorders. We herein present three cases of patients with IDA related to Glanzmann thrombasthenia and Bernard–Soulier syndrome, who have been successfully treated with FCM with increase in hemoglobin levels, reduced hospital visits and improvement in quality of life.
Dear editor, Iron deficiency anemia (IDA) is a frequent complication in inherited platelet function defects (PFDs) because of chronic and acute mucocutaneous bleedings. Oral iron supplementation is the mainstay of treatment of chronic IDA; however, it * Marco Capecchi [email protected] Natalia Scaramellini [email protected] Andrea Artoni [email protected] Silvia La Marca [email protected] Maria Domenica Cappellini [email protected] Irene Motta [email protected] 1
Università Degli Studi Di Milano, Milan, Italy
2
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Via Pace 9, 20122 Milan, Italy
3
Department of Internal Medicine, UOC Medicina Generale, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
can be insufficient to compensate for the losses and is often associated with gastrointestinal (GI) side effects, especially for long-term treatment. In the case of severe sub-acute anemia, physicians often use red blood cells (RBCs) transfusions to correct the level of anemia rapidly. Intravenous (IV) iron administration is indicated when oral compounds are not tolerated, in the presence of severe anemia (
Data Loading...
